Carbonic Anhydrase and Receptor Tyrosine Kinases (CA and RTK)

Carbonic Anhydrase and Receptor Tyrosine Kinases (RTKs) represent two distinct protein families that are frequently associated in the context of cancer therapy and physiological pH regulation. Carbonic Anhydrases are zinc-metalloenzymes that catalyze the hydration of carbon dioxide to bicarbonate and protons, playing a critical role in maintaining acid-base balance; isoforms such as CA IX and CA XII are often upregulated in hypoxic tumors to facilitate survival in acidic microenvironments (Supuran, 2008, Nature Reviews Drug Discovery). Receptor Tyrosine Kinases are high-affinity cell surface receptors for growth factors and hormones, mediating essential signal transduction pathways that govern cell proliferation and angiogenesis (Lemmon & Schlessinger, 2010, Cell). Research has demonstrated that several clinically approved RTK inhibitors, including sunitinib, pazopanib, and axitinib, also act as potent inhibitors of specific carbonic anhydrase isoforms, suggesting a multi-target mechanism that may enhance anti-tumor activity by simultaneously disrupting blood supply and pH regulation (Vullo et al., 2014, Journal of Enzyme Inhibition and Medicinal Chemistry). This dual inhibition strategy is particularly significant in treating renal cell carcinoma and other solid tumors where hypoxia-driven pathways are prominent.

Other names

Carbonic Anhydrase/RTK dual targetsCA/RTK combinationCarbonic Anhydrase and Receptor Tyrosine Kinase inhibitors

Simultaneous inhibition of carbonic anhydrase enzymes to disrupt intracellular/extracellular pH homeostasis and inhibition of receptor tyrosine kinase phosphorylation to block downstream growth factor signaling pathways.